Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46,282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
Liu F, Liu Y, Liu M, Wu G, Zhang M, Zhang X, Cui N, Yin H, Chen L. Liu F, et al. Among authors: liu y, liu m. J Diabetes Investig. 2021 Aug;12(8):1386-1394. doi: 10.1111/jdi.13504. Epub 2021 Feb 28. J Diabetes Investig. 2021. PMID: 33475222 Free PMC article. Clinical Trial.
More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.
Frias J, Puig Domingo M, Meneghini L, Napoli R, Liu M, Soltes Rak E, Aroda VR. Frias J, et al. Among authors: liu m. Diabetes Obes Metab. 2018 Sep;20(9):2314-2318. doi: 10.1111/dom.13368. Epub 2018 Jun 13. Diabetes Obes Metab. 2018. PMID: 29785837 Free PMC article.
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ. Rosenstock J, et al. Among authors: liu m. Diabetes Obes Metab. 2018 Dec;20(12):2821-2829. doi: 10.1111/dom.13462. Epub 2018 Aug 13. Diabetes Obes Metab. 2018. PMID: 29974618 Free PMC article.
Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis.
Tabák ÁG, Anderson J, Aschner P, Liu M, Saremi A, Stella P, Tinahones FJ, Wysham C, Meier JJ. Tabák ÁG, et al. Among authors: liu m. Diabetes Ther. 2020 Jan;11(1):305-318. doi: 10.1007/s13300-019-00735-7. Epub 2019 Dec 17. Diabetes Ther. 2020. PMID: 31848983 Free PMC article.
Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.
Del Prato S, Frias JP, Blonde L, Aroda VR, Shehadeh N, Saremi A, Dex T, Niemoeller E, Souhami E, Liu M, Rosenstock J. Del Prato S, et al. Among authors: liu m. Diabetes Obes Metab. 2020 Sep;22(9):1567-1576. doi: 10.1111/dom.14068. Epub 2020 May 28. Diabetes Obes Metab. 2020. PMID: 32323437 Free PMC article. Clinical Trial.
46,282 results
You have reached the last available page of results. Please see the User Guide for more information.